Update on management of infections in cancer and stem cell transplant patients

Area of Science:

• Oncology
• Infectious Diseases
• Hematology

Background:

• Infections are a primary cause of morbidity and mortality in patients with aggressive malignancies and those undergoing allogeneic stem cell transplantation.
• New therapeutic strategies and donor types present evolving infectious challenges, including viral, fungal, and antibiotic-resistant bacterial infections.

Purpose of the Study:

• To outline current strategies for managing infections in immunocompromised patients.
• To address the challenges posed by emerging pathogens and antibiotic resistance.
• To guide prompt and effective preemptive interventions for various infection types.

Main Methods:

• Empiric monotherapy with broad-spectrum antibiotics (piperacillin-tazobactam, cefepime, ceftazidime, carbapenem) for neutropenic fever.
• Preemptive antifungal therapy for lung infiltrates, targeting aspergilli.
• Addition of glycopeptides for catheter-related, skin, or soft tissue infections.
• Monitoring cytomegalovirus (CMV) antigen and polymerase chain reaction (PCR) to guide preemptive antiviral therapy (ganciclovir or foscarnet) in stem cell transplant recipients.

Main Results:

• Prompt empiric monotherapy is mandatory for high-risk neutropenic patients with fever.
• Early antifungal intervention is recommended for patients with lung infiltrates.
• Glycopeptide addition demonstrates a high response rate for specific infections.
• Serial CMV monitoring effectively guides preemptive antiviral treatment in stem cell transplant recipients.

Conclusions:

• Effective management of infections in immunocompromised patients requires prompt, targeted therapeutic strategies.
• Anticipating and addressing emerging resistance patterns and specific pathogens is crucial.
• Monitoring-guided preemptive therapy, particularly for viral infections like CMV, improves patient outcomes.